文献速递银屑病与炎症性皮肤病

一项多中心、随机、双盲、安慰剂对照、剂量范围研究评估vunakizumab在中重度斑块状银屑病患者中的疗效和安全性

A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis.
PubMed 文献 · J Am Acad Dermatol · 2022-01-10

这项36周、多中心、双盲、II期研究将187例中重度斑块状银屑病患者按1:1:1:1:1随机分配至vunakizumab 40、80、160、240 mg组或安慰剂组,每4周皮下给药至第12周。第12周时,各vunakizumab组达到PASI 75的比例均显著高于安慰剂组,未观察到意外不良效应。

要点

  • 第12周PASI 75应答率:vunakizumab 40、80、160、240 mg组分别为56.8%、65.8%、81.6%、86.5%,安慰剂组为5.4%(所有P<.001)。
  • 第12周PGA 0或1应答率:vunakizumab 40、80、160、240 mg组分别为45.9%、47.4%、60.5%、73.0%,安慰剂组为8.1%。
  • 作者结论:vunakizumab对中重度斑块状银屑病显示有前景的疗效且耐受性良好,需在更大规模和更长期的研究中进一步验证。

核心结论

  • Vunakizumab对中重度斑块状银屑病显示有前景的疗效且耐受性良好,需在更大规模和更长期的研究中进一步验证。

研究设计与样本

  • 36周、多中心、双盲、II期研究(NCT03463187),纳入187例中重度斑块状银屑病患者,按1:1:1:1:1随机分配至vunakizumab 40、80、160、240 mg组或安慰剂组,每4周皮下给药至第12周,vunakizumab组在第16周和第20周再给药2次。

主要发现

  • 第12周达到PASI 75的患者比例:vunakizumab 40 mg组56.8%、80 mg组65.8%、160 mg组81.6%、240 mg组86.5%,安慰剂组5.4%,所有vunakizumab组与安慰剂组比较P<.001。
  • 第12周达到PGA 0或1的患者比例:vunakizumab 40 mg组45.9%、80 mg组47.4%、160 mg组60.5%、240 mg组73.0%,安慰剂组8.1%。
  • 未观察到意外不良效应。

关键数值与推荐

  • 主要终点为第12周PASI较基线改善至少75%。
  • 第12周PASI 75应答率:vunakizumab 40 mg组56.8% vs 安慰剂组5.4%(P<.001)。
  • 第12周PASI 75应答率:vunakizumab 80 mg组65.8% vs 安慰剂组5.4%(P<.001)。
  • 第12周PASI 75应答率:vunakizumab 160 mg组81.6% vs 安慰剂组5.4%(P<.001)。
  • 第12周PASI 75应答率:vunakizumab 240 mg组86.5% vs 安慰剂组5.4%(P<.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究持续时间相对较短。
  • 未纳入阳性对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vunakizumab (SHR-1314) is a novel interleukin 17A monoclonal antibody that has shown preliminary efficacy and tolerability in phase I trials. OBJECTIVE: To evaluate the efficacy and safety of vunakizumab in moderate-to-severe plaque psoriasis. METHODS: In this 36-week, multicenter, double-blinded, phase II study (NCT03463187), 187 eligible patients with moderate-to-severe plaque psoriasis were randomized 1:1:1:1:1 to receive vunakizumab (40, 80, 160, or 240 mg) or placebo subcutaneously, every 4 weeks, until week 12 (2 more drug administrations for the vunakizumab groups on weeks 16 and 20). The primary end point was at least 75% improvement in the Psoriasis Area and Severity Index at week 12. RESULTS: At week 12, there were significantly greater proportions of responders with at least 75% improvement in the Psoriasis Area and Severity Index in all vunakizumab groups compared to placebo (40, 80, 160, and 240 mg: 56.8%, 65.8%, 81.6%, and 86.5%, respectively, vs 5.4%; P < .001 for all); the proportions of patients achieving Physician's Global Assessment responses of 0 or 1 were also higher with vunakizumab (45.9%, 47.4%, 60.5%, and 73.0%, respectively, vs 8.1%). No unexpected adverse effects were observed. LIMITATIONS: The study was relatively short in duration and included no active control. CONCLUSION: Vunakizumab showed promising efficacy for moderate-to-severe plaque psoriasis, with good tolerability, warranting further investigation in larger and longer-term studies.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Zhang C, Yan K, Diao Q, et al. A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2022. PMID: 35026342. doi:10.1016/j.jaad.2022.01.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。